Professor Kevin Winthrop, Professor of Medicine at Oregon Health & Science University. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Kevin Withrop discusses his paper on the safety of filgotinib in patients with RA.

Prof Iain McInnes reviews two papers this month, and discusses exposure-adjusted incidence rates of TEAEs and AESIs with filgotinib, as well as the efficacy and safety of tofacitinib in pJIA. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Professor Kevin Winthrop, Professor of Medicine at Oregon Health & Science University. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Kevin Withrop discusses his paper on the incidence and risk of herpes zoster in patients with RA receiving upadacitinib.

Prof Iain McInnes reviews two papers this month, and discusses the increased risk of HZ infection with upadacitinib, as well as the role of the JAK-STAT pathway in SpA pathenogenesis. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Professor Atul Deodhar, professor of medicine at Oregon Health & Science University. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Atul Deodhar discusses his review on JAK-STAT signalling in spondyloarthritis and what that means for the use of JAK inhibitors for SpA treatment.

Professor Roy Fleishmann, clinical professor of medicine at the University of Texas Southwestern Medical Center. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Roy Fleishmann discusses the effect of baricitinib on inhibiting radiographic progression of structural joint damage over 5 years in patients with active RA.

Prof Iain McInnes discusses the risk of herpes zoster in RA patients taking biologics and DMARDS. He also discusses reactivation of hepatitis B in patients with RA taking tofacitinib. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Paul Bird, Conjoint Professor at the University of South Wales. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Dr Paul Bird assess the real world evaluation of effectiveness, persistence, and usage patterns of monotherapy and combination therapy tofacitinib in treatment of rheumatoid arthritis in Australia.

Prof Iain McInnes discusses poor prognostics factors from the FINCH 3 study, and the effectiveness and persistence of monotherapy and combination therapy from the Australian OPAL study. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Kurt de Vlam, Professor of Rheumatology at UZ Leuven, Belgium. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor de Vlam assess the impact of baseline pain severity on pain response and the time to improvement in patients with PsA receiving tofacitinib.

Vibeke Strand, Adjunct Clinical Professor in the Division of Immunology/Rheumatology, Biopharmaceutical Consultant at Stanford University School of Medicine. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Strand discusses improvements in PROs in patients with RA treated with upadacitinib monotherapy.

Prof Iain McInnes discusses an essential part of the assessment of patients with rheumatic diseases; patient reported outcomes, or PROs. Improving PROs is crucial to effect tangible change in diseases and patient outcomes - to the extent that PROs are now included as an important component of many clinical trials. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Prof Iain McInnes discusses long-term data from the SELECT-PsA 2 study, and the impact of DMARDs on COVID-19 outcomes. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Philip Mease, Professor at the University of Washington School of Medicine in Seattle. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Mease discusses the longer-term safety and maintenance of efficacy of upadacitinib in patients with RA.

Jeffrey Sparks, Professor at Brigham and Women's Hospital in Boston, and Zachary Wallace, Professor at Massachusetts General Hospital. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professors Sparks and Wallace discuss the latest results from the COVID-19 Global Rheumatology Alliance physician registry.

Prof Iain McInnes discusses the main highlights of EULAR 2021 and the key takeaway messages. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Francesco Ciccia, Assistant Professor of Rheumatology at the University of Palermo in Italy. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Ciccia discusses with Professor Nash the impact of pain in patients with rheumatic diseases and the physiological basis of modulating nociceptive pain, speculating that JAK inhibitors may have a dual therapeutic role.

Stanley Cohen, Clinical Professor in the Department of Internal Medicine and Co-Director of the Division of Rheumatology from the UT Southwestern Medical Center and Presbyterian Hospital, Dallas. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Cohen discusses radiographic progression in patients with RA treated with tofacitinib.

Dr Elena Nikiphorou presents the Day 4 highlights of the key abstracts and posters presented at EULAR 2021.

Professor Douglas Veale presents the Day 3 highlights of the key abstracts and posters presented at EULAR 2021.

Dr Elena Nikiphorou presents the Day 2 highlights of the key abstracts and posters presented at EULAR 2021.

Prof Veale presents the Day 1 highlights of the key abstracts and posters presented at EULAR 2021.

A preview of the latest research at EULAR 2021.
Prof Edwards presents a preview of the upcoming EULAR 2021 congress, highlighting important abstracts and posters in cytokine signalling.

Prof Iain McInnes discusses upadacitinib in PsA, and radiographic progression with tofacitinib. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Yoshiya Tanaka, Professor and Chairman of the department of Internal Medicine at the University of Occupational and Environmental Health in Kitakyushu, Japan. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Tanaka discusses the safety and efficacy of filgotinib as a Novel JAK1-Preferential Inhibitor for the Treatment of RA.

Dr Rishi Desai, is an Assistant Professor of Medicine at Harvard Medical School and an Associate Epidemiologist in the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Dr Rishi Desai discusses Risk of venous thromboembolism associated with tofacitinib in patients with RA

Prof Iain McInnes discusses JAKi and thromboembolism Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Dr Ben Nowell, Director of Patient-Centred Research at CreakyJoints, part of the Global Healthy Living Foundation. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Dr Ben Nowell a real-world longitudinal study in ArthritisPower

Prof Iain McInnes discusses bone metabolism and PRO Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Professor Paul Emery, an arthritis Research UK Professor of Rheumatology, and Director of the Leeds Musculoskeletal Biomedical Research Centre at Leeds Teaching Hospitals Trust, UK. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Paul discusses how baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis

Professor Leonard Calabrese offers the latest advice on managing rheumatic patients during the pandemic and Professor Kimme Hyrich discusses the learnings from the COVID-19 Global Rheumatology Alliance registries, a year on from their inception.

Dr Lee Simon, Principal Scientist in SDG LLG, Cambridge, US. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Dr Lee Simon discusses pain in RA

Professor Tsutomu Takeuchi, Vice-President at Keio University and Professor of Medicine in the Division of Rheumatology and Clinical Immunology at Keio University School of Medicine. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Tsutomu Takeuchi discusses how upadacitinib monotherapy vs methotrexate monotherapy in methotrexate-naïve Japanese patients with RA

Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Professor René Westhovens discusses his latest paper on use of filgotinib in combination with methotrexate or as filgotinib monotherapy versus methotrexate monotherapy in patients with active RA.

Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Founder and President of the Association of Women in Rheumatology. In this podcast Dr Grace Wright discusses her career and the future of AWIR.

Professor György Nagy from the Semmelweis University, Hungry. Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Professor György Nagy discusses his latest paper on EULAR definition of difficult-to-treat RA

Professor Philip Mease from the University of Washington School of Medicine. Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Professor Philip Mease discusses his latest paper on Upadacitinib for Psoriatic Arthritis refractory to biologics.

Prof Iain McInnes discusses JAK inhibitors and TNFi in RA treatment. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

In this podcast the Past President of ACR, Professor Michael Weinblatt discusses his involvement in the development of methotrexate and the expansion of his unit at the Brigham, alongside Professor Paul Emery.

Prof Josef Smolen from Medical University of Vienna. Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Prof Josef Smolen discusses efficacy of baricitinib in patients with RA

Professor Roy Fleischmann, from the University of Texas Southwestern Medical Centre in Dallas, discusses data from the SELECT-COMPARE trial, where patients with RA were switched between upadacitinib and adalimumab in cases of insufficient response.

Dr Andreas Kerschbaumer from Vienna University. Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Dr Andreas Kerschbaumer discusses his systematic review paper on “Points to Consider for the Treatment of Immune Mediated Inflammatory Diseases with Janus Kinase Inhibitors.

Prof Iain McInnes discusses JAK inhibitors. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Prof Kevin Winthrop from OHSU. Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Prof Kevin Winthrop discusses aged based incidence of infections with tofacitinib

Past President of EULAR and Carol Nachman Prize winner. In this podcast, Professor Paul Emery discusses his work in managing early RA and the growth of his unit at Leeds into a world leading centre for rheumatology research alongside Professor Michael Weinblatt.

Prof Iain McInnes discusses upadacitinib safety. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Prof Stanley Cohen - University of Texas. Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Prof Stanley Cohen discusses safety profile of upadacitinib

Dr Gustavo Citera, Head of Rheumatology at the Institute of Psychophysical Rehabilitation, Buenos Aires, Argentina. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Dr Gustavo Citera discusses how JAK inhibition could be associated with interstitial lung disease events.

Prof Iain McInnes discusses the use of baricitinib to treat COVID-19 and a JAK inhibitor, itacitinib. Keep up-to-date with the latest information in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed in this podcast is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Professor of Rheumatology at University Medical Centre, Utrecht. In this podcast, Professor Bijlsma discusses what attracted him to the field of rheumatology, the major advances in immunological knowledge leading to tsDMARDs and the importance of Treat-to-Target. Perspectives in Inflammation is a series of in-depth interviews revealing what attracted world leading experts to the field of inflammation, their current research, and views on developments in inflammation.

Professor of Rheumatology in the Department of Internal Medicine - Hospital de Clínicas at the Federal University of Paraná, Brazil. In this podcast, Professor Azevedo discusses what attracted him to rheumatology and how biosimilars have evolved in Latin America.

Dr Pedro López-Romero, a senior research scientist from Lilly, and Dr Eugen Feist from the Charité. Join Prof Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, they discuss anti-CarbV and anti-MCV titres as predictors for improvements in SDAI score and radiographic progression in patients with RA.

Kevin Winthrop, Professor of Infectious Diseases and Public Health at the Oregon Health & Science University in Portland, Oregon. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Kevin Winthrop discusses infections in baricitinib clinical trials for patients with active RA.

Prof Iain McInnes discusses the risk of infection and cardiovascular events associated with JAK inhibitors. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed in this podcast is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Pharmacoepidemiology research group leader at the German Rheumatism Research Centre, Berlin, Germany, and Scientific Director of the Institute of Musculoskeletal Health, Madrid, Spain. In this podcast, Professor Strangfeld and Professor Carmona discuss the use of registries in the field of rheumatology, giving insight into their experiences with developing data collection strategies over the years and translating it to clinical research.

Vice Chair of the Cleveland Clinic's Department of Rheumatic and Immunologic Diseases in Cleveland, Ohio. In this podcast, Prof Leonard Calabrese discusses his interest in rheumatology, his work considering the interface between rheumatic diseases and infection, and the significance of herpes zoster in inflammatory disease. Perspectives in Inflammation is a series of in-depth interviews revealing what attracted world leading experts to the field of inflammation, their current research interests, and views on the latest developments in inflammation.

Vibeke Strand, Adjunct Clinical Professor in the Division of Immunology and Rheumatology in the Stanford University School of Medicine. Join Prof Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Vibeke Strand discusses the safety and efficacy of upadacitinib monotherapy in RA.

Chair of Department of Rheumatology in the Hospital Italiano, Buenos Aires, Argentina. In this podcast, Dr Soriano discusses his interest in Rheumatology, and his current research collaboration across Argentina.

Professor Roy Fleischmann from the University of Texas Southwestern Medical Center, Dallas. Join Prof Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Roy Fleischmann discusses the safety and efficacy of long-term baricitinib monotherapy in RA.

Prof Iain McInnes discusses the safety and efficacy of baricitinib and upadacitinib monotherapy in RA management. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed in this podcast is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Chief of the Allergy Immunology and Rheumatology Division and Executive Committee Member of the Center for Musculoskeletal Research. In this podcast, Prof Chris Ritchlin discusses how he became involved in rheumatology.

Prof Kosuke Ebina from the University of Osaka, Japan. Join Prof Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Kosuke Ebina discusses drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with RA using real-world data from the ANSWER registry.

Professor Georg Schett from the University of Erlangen-Nuremberg. Join Prof Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Georg Schett discusses SARS-CoV-2 seroconversion in patients with immune-mediated inflammatory diseases receiving cytokine inhibitors.

Prof Iain McInnes discusses the long term safety of tofacitinib in PsA and drug retention.
Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed in this podcast is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Past president of EULAR, incoming president of ILAR and the Associate Editor of the Journal of Clinical and Experimental Rheumatology. In this podcast, Prof Maurizio Cutolo discusses circadian rhythms in inflammation alongside Prof Kevin Winthrop from Oregon Health and Science University.

Kennedy Professor of Translational Rheumatology at the Universities of Birmingham and Oxford.
In this podcast, Prof Chris Buckley discusses his contribution to A-TAP for which he received the prestigious Carol Nachman prize in 2020.

Professor Axel Finckh from the Universirty of Geneva.
Join Prof Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Axel Finckh discusses drug maintenacne in a Swiss RA population.

Dr Stanley Cohen from Southwestern Medical School. Join Prof Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Dr Stanley Cohen discusses a phase 2 trial of BTK inhibitor, fenebrutinib.

Professor Gerd Burmester from the Charité. Join Prof Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Gerd Burmester discusses the safety of tofacitinib in PsA and evaluates Hep B in baricitinib trials.

Prof Iain McInnes discusses the safety profile and temporary interruption of baricitinib.
Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed in this podcast is available in a more detailed slide format in the publications section.

Gain insight into the latest research presented at EULAR 2020.
Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors. This edition includes some great basic science abstracts from Professor Iain McInnes and Professor Thomas Dörner.

Gain insight into the latest research presented at EULAR 2020.
Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors. This edition focuses on the safety of JAK inhibitors and features presentations from; Professor Leonard Calabrese, Professor Kevin Winthrop, Professor Iain McInnes and Professor Anja Strangfeld.

Gain insight into the latest research presented at EULAR 2020. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors. This edition focuses on JAK inhibitors featuring presentations from; Professor Maya Buch, Professor Paul Emery, Professor Roy Fleischmann, Professor Peter Nash and Dr Kim Lauper

Gain insight into the latest research presented at EULAR 2020. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors. This edition focuses on patient reported outcomes and real-world data featuring presentations from; Professor Rieke Alten, Professor Vibeke Strand, Professor Axel Finckh, and Dr Kelly Gavigan.

Gain insight into the latest research presented at EULAR 2020. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors. This edition focuses on JAK inhibitors and emerging treatments in therapy areas beyond RA, featuring presentations from; Professor Peter Nash, Professor Xenofon Baraliakos, Professor Atul Deodhar, Professor David Isenberg.

Prof Edwards presents the Day 4 highlights of the key abstracts and posters presented at EULAR 2020.

Prof Edwards presents the Day 3 highlights of the key abstracts and posters presented at EULAR 2020.

Prof Bijlsma presents the Day 2 highlights of the key abstracts and posters presented at EULAR 2020.

Prof Bijlsma presents the Day 1 highlights of the key abstracts and posters presented at EULAR 2020.

A preview of the latest research at EULAR 2020.
Prof Bijlsma presents a preview of the upcoming EULAR 2020 congress, highlighting important abstracts in cytokine signalling.

Prof Iain McInnes discusses PsA & Hep B.
Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed in this podcast is available in a more detailed slide format in the publications section.

The global effort improving patient outcomes amid COVID-19.
Prof Peter Nash discusses the global rheumatology register for COVID-19 with Prof Philip Robinson.

Prof Kevin Winthrop from Oregon Health & Science University.
Join Prof Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition Prof Kevin Winthrop discusses the long-term effectiveness of the live zoster vaccine

Prof Iain McInnes discusses vasculitis and zoster.
Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed in this podcast is available in a more detailed slide format in the publications section.

The global effort improving patient outcomes amid COVID-19.
Past President of EULAR Prof Johannes Bijlsma discusses global rheumatology registries for COVID-19 with EULAR registry group member Prof Kimme Hyrich.

COVID-19 guidance for rheumatologists.
Prof Peter Nash discusses the challenges COVID-19 poses with infections specialist Prof Kevin Winthrop.

First to identify destructive properties of IL-17 and received the prestigious Carol Nachman prize in 2010 for his contribution. In this podcast, Prof Pierre Miossec discusses the pathophysiology of RA alongside Prof Tsutomu Takeuchi from Keio University.

Timo Gaber and Paula Hoff from Charité Berlin.
Join Prof Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, the impact of tofacitinib on the bone healing process is discussed.

Prof Schett from University of Erlangen-Nuremberg.
Join Prof Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Prof Schett discusses how JAK inhibitors can increase bone formation by stimulating osteoblasts.

Prof Iain McInnes discusses bone homeostasis.
Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed in this podcast is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Muirhead Professor of Medicine, President of EULAR, and Sir James Black Prize Medal winner. In this podcast, Prof Iain McInnes discusses the inception of JAK inhibitors during his time at the National Institutes of Health with Prof Peter Nash from the University of Queensland.

Dr Giovanni Orsolini from the University of Verona.
Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Dr Giovanni Orsolini discusses the potential of JAK inhibitors to halt bone erosion, independent of their effects on inflammation.

Prof Iain McInnes discusses JAK selectivity.
Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Head of the Division of Rheumatology at Karolinska Institute and a co-author of more than 100 articles in peer review journals. In this podcast, Prof Anca Catrina discusses the role of antibodies in the pathogenesis of RA with Prof Johannes Bijlsma from University Medical Centre, Utrecht.

Prof Vibeke Strand from Stanford University.
Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Prof Vibeke Strand discusses improvements in patient-reported outcomes with upadacitinib.
Effects of Upadacitinib on Patient-Reported Outcomes: Results from SELECT-BEYOND and SELECT-NEXT.

Safety of Baricitinib in East Asian Patients With Moderate to Severe Active Rheumatoid Arthritis

Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis

Professor McInnes presents the Highlights of 2019.
We can be optimistic that clinical practice for inflammatory arthritis will continue to improve, with promising long-term safety data supporting the use of established JAK inhibitors; tofacitinib and baricitinib, in addition to exciting phase III clinical data for filgotinib and newly approved upadacitinib.

A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis...

Comparative Efficacy and Safety of Peficitinib 25, 50, 100, and 150 mg in Patients with Active Rheumatoid Arthritis: A Bayesian Network Meta?Analysis of Randomized Controlled Trials...

In this edition of Congress Author Podcasts, recorded at ACR 2019, the latest data from the FINCH studies are presented by Professors Taylor, Westhovens and Winthrop, in addition to filgotinib safety data from a phase 2 Psoriatic Arthritis trial, presented by Professor Coates.

Download the Posters Here

In this edition of Congress Author Podcasts, recorded at ACR 2019,
real-world tofacitinib safety data is presented by Professor Joel Kremer and the impact of baricitinib and tofacitinib on pain is analysed by Professors Peter Taylor and Maxime Dougados.

Download the Posters Here

Introducing Congress Author Podcasts, a new podcast series where authors review their congress posters and presentations on cytokine signalling and JAK inhibitors. The first edition, recorded at ACR 2019 in Atlanta, focuses on upadacitinib.

Download the Posters Here

Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function

Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib

Professor Iain McInnes joined by Professor Johannes Bijlsma, discusses the changes required to educate the next generation of rheumatologists, highlighting the benefits of online educational courses and the importance of quality amid a plethora of information.

Comparison of Baricitinib, Upadacitinib, and Tofacitinib Mediated Regulation of Cytokine Signalling in Human Leukocyte Subpopulations...

Outcomes of Dose Reduction, Withdrawal, and Restart of Tofacitinib in Patients with Rheumatoid Arthritis: A Prospective Observational Study...

Safety and Effectiveness of Upadacitinib or Adalimumab Plus Methotrexate in Patients with Rheumatoid Arthritis Over 48 Weeks with Switch to Alternate Therapy in Patients with Insufficient Response....
Upadacitinib versus Placebo or Adalimumab in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase 3, Double-Blind, Randomized Controlled Trial....

Live Zoster Vaccine in Patients with Rheumatoid Arthritis Treated with Tofacitinib with or without Methotrexate, or Adalimumab with Methotrexate....

Safety and Effectiveness of Upadacitinib or Adalimumab Plus Methotrexate in Patients with Rheumatoid Arthritis Over 48 Weeks...

Efficacy and Safety of Peficitinib (ASP015K) in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate...

Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models....

Clinical Outcomes in Patients Switched from ADA to BARI due to Non-response and/or Study Design: Phase III in Patients with Rheumatoid Arthritis...

Live Zoster Vaccine in Patients with Rheumatoid Arthritis Treated with Tofacitinib with or without Methotrexate, or Adalimumab with Methotrexate...

Upadacitinib as Monotherapy in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate (SELECT-MONOTHERAPY)...

Impact of Janus Kinase Inhibitors on Risk of Cardiovascular Events in Patients with Rheumatoid Arthritis...

Evaluation of Pneumococcal and Tetanus Vaccine Responses in Patients with Rheumatoid Arthritis Receiving Baricitinib: Results from a Long-Term Extension Trial Substudy....

Evaluation of Pneumococcal and Tetanus Vaccine Responses in Patients with Rheumatoid Arthritis Receiving Baricitinib: Results from a Long-Term Extension Trial Substudy...

Safety and Efficacy of Tofacitinib For Up to 9.5-Years in The Treatment of Rheumatoid Arthritis: Final Results of a Global, Open-Label, Long-Term Extension Study...

Efficacy and Safety Data Based on Historical or Pre-Existing Conditions at Baseline for Patients with Active Rheumatoid Arthritis Who Were Treated with Baricitinib....

Efficacy and Safety Data Based on Historical or Pre-Existing Conditions at Baseline for Patients with Active Rheumatoid Arthritis Who Were Treated with Baricitinib...

Tuberculosis, Hepatitis B and Herpes Zoster in Tofacitinib-Treated Patients with Rheumatoid Arthritis...

Safety Profile of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis with Over 1.6 Years Median Time in Treatment: An Integrated Analysis of Phase 2 and 3 Trials....

Professor McInnes reviews 3 abstracts presented at ACR which analyse the relationship between JAK inhibitors and pain in patients with rheumatoid arthritis.

Click here to download the Powerpoint slides...

Baricitinib Induces LDL-C and HDL-C Increases in Rheumatoid Arthritis: A Meta-Analysis of Randomized Controlled Trials...

Network Meta-Analysis of Tofacitinib versus Biologic Treatments in Moderate-to-Severe Rheumatoid Arthritis Patients...

Characterization and Changes of Lymphocyte Subsets in Baricitinib-Treated Patients With Rheumatoid Arthritis: An Integrated Analysis....

Cardiovascular Safety During Treatment with Baricitinib in Rheumatoid Arthritis...

Tofacitinib in Combination with Methotrexate in Patients with Rheumatoid Arthritis: Clinical Efficacy, Radiographic and Safety Outcomes from the 24-Month Phase 3 ORAL Scan Study...

Characterization and Changes of Lymphocyte Subsets in Baricitinib-Treated Patients With Rheumatoid Arthritis: An Integrated Analysis...

A Pooled analysis of the Safety of Tofacitinib as Monotherapy or in Combination with Background Conventional Synthetic Disease-Modifying Antirheumatic Drugs in a Phase 3 Rheumatoid Arthritis Population...

Influence of Age and Renal Impairment on the Steady State Pharmacokinetics of Filgotinib, a Selective JAK1 Inhibitor...

Evaluation of the Short-, Mid-, and Long-term Effects of Tofacitinib on Lymphocytes in Patients with Rheumatoid Arthritis...

Influence of Age and Renal Impairment on the Steady State Pharmacokinetics of Filgotinib...

Herpes zoster in Tofacitinib: Risk is Further Increased with Glucocorticoids but not Methotrexate...

Safety and Efficacy of Baricitinib in Patients Receiving Conventional Synthetic Disease-Modifying Antirheumatic Drugs or Corticosteroids...

Herpes zoster in Tofacitinib: Risk is Further Increased with Glucocorticoids but not Methotrexate...

- Dr Alan Kivitz discussing his SYK inhibitor data: 00:00-2:09
- Dr Rebecca Kunder talks about the FIL safety study: 2:10-8:12
- Dr Heather Litman describes real-world immunomodulator data: 8:13-10:55
- Professor Roy Fleischmann analyses BARI rescue data: 10.56-15.02
- Dr Lucia Domínguez-Casas reviewes respiratory infection factors: 15.03-17:00
- Professor Peter Taylor with Dr Amer Mirza discuss JAK inhibitor biomarkers: 17:01-18:57

Dose Reduction of Baricitinib in Patients with Rheumatoid Arthritis Achieving Sustained Disease Control: Results of a Prospective Study...

Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment...

Sustained Response Following Discontinuation of Methotrexate in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab...

Lipid Profile and Effect of Statin Treatment in Pooled Phase II and Phase III Baricitinib Studies...

Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis...

Tocilizumab Discontinuation After Attaining Remission in Patients with Rheumatoid Arthritis who were Treated with Tocilizumab Alone or in Combination with Methotrexate...

Two Years of Sarilumab in Patients with Rheumatoid Arthritis and an Inadequate Response to MTX...

Adverse Events, Clinical Considerations and Management Recommendations in Rheumatoid Arthritis Patients Treated with JAK Inhibitors...

Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (SELECT-NEXT)...
Safety and Efficacy of Upadacitinib in Patients with Active Rheumatoid Arthritis Refractory To Biologic Disease-Modifying Anti-Rheumatic Drugs (SELECT-BEYOND)...

Long-term Radiographic and Patient-reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib...
Effects of Baricitinib on Radiographic Progression of Structural Joint Damage at 1 year...

Evaluation of Disease Activity in Patients with Rheumatoid Arthritis Treated with Tofacitinib by RAPID3: Post Hoc Analyses from Two Phase 3 Trials...

Tofacitinib in Rhuematoid Arthritis: Lack of Early Change in Disease Activity Predicts...
Evaluation of Disease Activity in Patients with Rheumatoid Arthritis Treated with Tofacitinib by RAPID3..

Effectiveness and Safety of Tofacitinib in Rheumatoid Arthritis: a Cohort Study...
Effect of Filgotinib, a Selective JAK1 Inhibitor, with or without Methotrexate in Patients with Rheumatoid Arthritis: Patient-Reported Outcomes..

Response to Baricitinib based on Prior Biologic Use in Patients with Refractory Arthritis...

Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc Analysis...

Worldwide, 3-year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis...

Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc Analysis...

Tofacitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Chinese Patients with Rheumatoid Arthritis: Patient-reported Outcomes...

Radiographic Joint Damage in Early Rheumatoid Arthritis Patients: Comparing Tocilizumab- and Methotrexate-based...

Radiographic Joint Damage in Early Rheumatoid Arthritis Patients: Comparing Tocilizumab- and Methotrexate-based Treat-to-target Strategies...

Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common framework phase 4 study programme TOZURA conducted in 22 countries...

Patient-Reported Outcomes in Newly Diagnosed Early Rheumatoid Arthritis Patients Treated to Target with a Tocilizumab- or Methotrexate-based Strategy...

Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including...

Long-term Effectiveness of Tocilizumab in Patients with Rheumatoid Arthritis, Stratified by Number of Previous Treatment Failures with Biologic Agents: Results from the German RABBIT Cohort...

Tofacitinib Therapy for Rheumatoid Arthritis: A Direct Comparison Study between Biologic-naive and Experienced Patients...

Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA...

Safety and Efficacy of Baricitinib in Elderly Patients with Rheumatoid Arthritis...

Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program...

Patient-reported Outcomes of Baricitinib in Patients with Rheumatoid Arthritis and...

Patient-reported Outcomes from a Phase 3 Study of Baricitinib versus...

Herpes Zoster and Tofacitinib Therapy in Patients with Rheumatoid Arthritis...

Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor...

Analysis of Non-melanoma Skin Cancer across the Tofacitinib ...

Efficacy and Safety of Tofacitinib Monotherapy...

Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib...

Outcomes of Tumor Necrosis Factor Inhibitor Cycling versus...

Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor...

Biologics or Tofacitinib for People with Rheumatoid Arthritis Naïve to Methotrexate...

EULAR RA Management Task Force, Ann Rheum Dis Published Online First: 06March2017. doi:10.1136/annrheumdis-2016-210715

Winthrop, Nature Reviews Rheumatology 2017;13:234–43

Aletaha et al, Lancet 2017;pii:S0140-6736(17)30401-4

Curits et al, Clin Exp Rheumatol 2017 Jan 4

Prof. McInnes reviews the latest papers uploaded to the Cytokine Signalling Forum

Prof. McInnes reviews the latest papers uploaded to the Cytokine Signalling Forum

Prof. McInnes presents the CSF monthly podcast reviewing papers from Prof. Genovese and Prof. Takeuchi
View our CME Courses

Prof. McInnes presents the CSF monthly podcast reviewing papers from Prof. J Zhang and Prof. Y Kaneko

Prof. McInnes presents the CSF monthly podcast reviewing papers from Prof. Laure Gossec

Prof. McInnes presents the CSF monthly podcast reviewing papers from Prof. V Strand and Prof. C Gabay.

Steering Committee chair Prof. Iain McInnes introduces his picks of the most important abstracts presented at ACR 2015.

Prof. Iain McInnes presents the inaugural monthly podcast reviewing papers by Prof. Wei Gao and Prof. Cem Gabay focusing on tofacitinib and tocilizumab respectively.